Clinical Trials Directory

Trials / Unknown

UnknownNCT05686707

Characterization of Different Phenotypes of Microvascular Dysfunction and Their Impact on Angina Severity in Patients With Chronic Angina in the Absence of Obstructive Coronary Artery Disease.

Characterization of Different Phenotypes of Microvascular Dysfunction and Their Impact on Angina Severity in Patients With Chronic Angina in the Absence of Obstructive Coronary Artery Disease

Status
Unknown
Phase
Study type
Observational
Enrollment
400 (estimated)
Sponsor
Federico II University · Academic / Other
Sex
All
Age
18 Years – 85 Years
Healthy volunteers
Not accepted

Summary

The aim of the present study will be to identify different phenotypes of microvascular dysfunction and their associations with the severity of anginal symptoms assessed through the Seattle Angina Questionnaire(SAQ-7).

Detailed description

After administration of unfractionated heparin (100UI/Kg), a special pressure guide (Pressure Wire X, Abbott), equipped with a distal sensor capable of measuring pressure and temperature, will be introduced inside the anterior descending branch (IVA) of the left coronary artery and hyperemia will be induced by intravenous infusion of adenosine. The IMR will be calculated using the thermodilution technique, and is given by the product between the mean distal pressure, in the left anterior descending coronary artery, and the mean transit time (Tmn) during maximal hyperemia. During the procedure, additional coronary physiological indices will be calculated such as: * Quiescent full cycle flow ratio (RFR), - Fractional flow reserve (FFR), * Coronary flow reserve (CFR) In order to identify different phenotypes of microvascular dysfunction, as follows: * Phenotype A: Patients with IMR\>25, CFR \<2 and FFR\>0.80 (concordant pure-microvascular pathological results) * Phenotype B: patients with IMR\>25, CFR\>2 and FFR\>0.80 (increased microvascular hyperemic resistance, maintenance of microvascular reactivity) * Phenotype C: Patients with IMR 25, CFR 2 and FFR\>0.80 (normal hyperemic resistance and reduced reactivity) All these phenotypes can also be combined with pathological FFR measures (\<0.80) (phenotypes A1, B1, C1).

Conditions

Timeline

Start date
2022-07-18
Primary completion
2024-12-31
Completion
2025-06-30
First posted
2023-01-17
Last updated
2024-03-06

Locations

1 site across 1 country: Italy

Source: ClinicalTrials.gov record NCT05686707. Inclusion in this directory is not an endorsement.